title: Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses.
abstract: The SNP (c.1142G > A;p.R381Q) in the IL-23 receptor (IL23R) confers protection from multiple inflammatory diseases, representing one of the most significant human genetic polymorphisms in autoimmunity. We, therefore, sought to define the functional consequences of this clinically significant variant. We find that CD4+CD45RO+ and CD8+ T cells from healthy R381Q IL23R carriers show decreased IL-23-dependent IL-17 and IL-22 production relative to WT IL23R individuals. This was associated with a lower percentage of circulating Th17 and Tc17 cells. Furthermore, CD8+ T cells from R381Q IL23R individuals showed decreased IL-23-dependent expansion and signal transducer and activator of transcription 3 (STAT3) activation compared with WT CD8+ T cells. Importantly, cells transfected with the IL23R glutamine variant show decreased IL-23-mediated signaling compared with the IL23R arginine allele. Our results show that the R381Q IL23R variant leads to selective, potentially desirable, loss of function alterations in primary human CD4+ and CD8+ T cells, resulting in highly significant protection against autoimmunity.
authors: Department of Internal Medicine, Section of Digestive Diseases, Yale University, New Haven, CT 06520, USA.
authors: Ritu
authors: R
authors: Sarin
authors: Xingxin
authors: X
authors: Wu
authors: Clara
authors: C
authors: Abraham
references: J Immunol. 2009 May 1;182(9):5296-305
references: 19380776
references: J Immunol Methods. 2008 Apr 20;333(1-2):115-25
references: 18314131
references: Nat Immunol. 2007 Sep;8(9):967-74
references: 17581537
references: Nat Genet. 2008 Aug;40(8):955-62
references: 18587394
references: Am J Hum Genet. 2007 Feb;80(2):273-90
references: 17236132
references: Semin Cell Dev Biol. 2008 Aug;19(4):311-8
references: 18765289
references: Science. 2008 Jul 18;321(5887):408-11
references: 18635804
references: Annu Rev Med. 2009;60:97-110
references: 18976050
references: Nat Immunol. 2009 Mar;10(3):314-24
references: 19182808
references: Nature. 2007 Jul 26;448(7152):480-3
references: 17581589
references: J Clin Invest. 2006 May;116(5):1310-6
references: 16670770
references: Mol Immunol. 2008 Sep;45(15):3889-95
references: 18675459
references: Nat Immunol. 2005 Nov;6(11):1133-41
references: 16200068
references: Nat Immunol. 2007 Sep;8(9):950-7
references: 17676044
references: J Immunol. 2009 Feb 15;182(4):1794-8
references: 19201830
references: J Immunol. 2009 Jul 1;183(1):381-7
references: 19542449
references: J Immunol. 2006 May 1;176(9):5652-61
references: 16622035
references: Gastroenterology. 2007 Jun;132(7):2359-70
references: 17570211
references: Immunity. 2000 Nov;13(5):715-25
references: 11114383
references: Nat Immunol. 2008 Jun;9(6):650-7
references: 18454150
references: Nature. 2003 Feb 13;421(6924):744-8
references: 12610626
references: J Exp Med. 2007 Aug 6;204(8):1849-61
references: 17635957
references: J Exp Med. 2008 Jul 7;205(7):1543-50
references: 18591412
references: J Exp Med. 2006 Oct 30;203(11):2473-83
references: 17030949
references: Eur J Immunol. 2009 Jul;39(7):1716-25
references: 19544308
references: Trends Immunol. 2006 Jan;27(1):17-23
references: 16290228
references: Nature. 2007 Jun 7;447(7145):661-78
references: 17554300
references: J Immunol. 2002 Jun 1;168(11):5699-708
references: 12023369
references: J Exp Med. 2008 Aug 4;205(8):1903-16
references: 18663128
references: Nat Immunol. 2007 Jun;8(6):639-46
references: 17486092
references: Arthritis Rheum. 2007 Sep;56(9):2936-46
references: 17763419
references: Science. 2006 Dec 1;314(5804):1461-3
references: 17068223
references: J Immunol. 2009 May 15;182(10):5904-8
references: 19414740
references: Immunol Rev. 2008 Dec;226:147-59
references: 19161422